Show simple item record

dc.contributor.authorHolmøy, Trygve
dc.contributor.authorTorkildsen, Øivind Fredvik
dc.contributor.authorMyhr, Kjell-Morten
dc.date.accessioned2019-07-11T08:50:20Z
dc.date.available2019-07-11T08:50:20Z
dc.date.issued2017-09-11
dc.identifier.citationHolmoy, T., Torkildsen, O., & Myhr, K. M. (2017). An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opin Pharmacother, 18(15), 1627-1635. doi:10.1080/14656566.2017.1372747en
dc.identifier.issn1465-6566
dc.identifier.urihttps://hdl.handle.net/10642/7264
dc.description.abstractINTRODUCTION: Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and safety issues, as well as high cost. Cladribine was originally rejected by the regulatory authorities in both the European Union and USA in 2011, but in June 2017 the European Medical Agency recommended marketing authorization for treatment of aggressive relapsing MS. Areas covered: We provide an update on chemistry, mechanism of action, efficacy and safety of cladribine for the treatment of MS. Expert opinion: Cladribine is well tolerated, it is dosed orally in cycles of one year, the need for regular blood testing during treatment is likely limited, and the two-year efficacy data for treatment of relapsing MS are at least in the same range as the most efficient licensed treatments. The increased risk of malignancies reported in the pivotal trial seems to be caused by unexpectedly low numbers of malignancies in the placebo group. Cladribine could therefore be an alternative for many patients with relapsing remitting MS. The main caveat is the lack of long term efficacy and safety data. Currently there are insufficient data to guide further treatment of patients who have completed two treatment cycles of cladribine.en
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.ispartofseriesExpert Opinion on Pharmacotherapy;18(15)
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis Expert Opinion on Pharmacotherapy on 11/09/2017, available online: https://www.tandfonline.com/doi/full/10.1080/14656566.2017.1372747en
dc.subjectVDP::Medisinske Fag: 700en
dc.subjectArtikkelen
dc.titleAn update on cladribine for relapsing-remitting multiple sclerosisen
dc.typeJournal articleen
dc.typePeer revieweden
dc.description.versionacceptedVersionen
dc.identifier.doihttp://dx.doi.org/10.1080/14656566.2017.1372747


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record